Evidence map›Paper›PMID 38369592›Full record

ArticleJournal of endocrinological investigation2024

Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.

B M Bonora, G Russo, F Leonetti, M Strazzabosco, L Nollino, G Aimaretti, A Giaccari, F Broglio, A Consoli, A Avogaro and 2 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Suitability and Usefulness of a Flexible Dosing Timing of Oral Semaglutide to Maximize Benefit in Clinical Practice: An Expert Panel.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

B M BonoraDepartment of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy.
G RussoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
F LeonettiDepartment of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy.
M StrazzaboscoDiabetology and Metabolic Diseases Unit, S. Bortolo Hospital, Vicenza, Italy.
L NollinoDepartment of Medicine, Diabetology Service, Azienda ULSS 2 Marca Trevigiana, Treviso, Italy.
G AimarettiEndocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
A GiaccariCentro per le Malattie Endocrine e Metaboliche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.
F BroglioDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
A ConsoliEndocrinology and Metabolism Unit, ASL, Pescara, Italy.
A AvogaroDepartment of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy.
G P FadiniDepartment of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy. gianpaolo.fadini@unipd.it.ORCID http://orcid.org/0000-0002-6510-2097
GLIMPLES Study Investigators
University of Padua · ITAULSS 2 Marca Trevigiana · ITOspedale San Bortolo · ITSapienza University of Rome · ITUniversità Cattolica del Sacro Cuore · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Chieti-Pescara · ITUniversity of Messina · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimOral semaglutide, an innovative orally administered GLP-1 receptor agonist for type 2 diabetes (T2D) management was herein evaluated for its effectiveness in a multi-center retrospective real-world study.

methodsWe included new-users of oral semaglutide from 18 specialist care centres and collected retrospective data on baseline clinical characteristics. Updated values of HbA1c and body weight were analyzed using the mixed model for repeated measures.

resultsThe study included 166 individuals with T2D, predominantly men (64.5%), with a mean age of 64.4 years and a mean diabetes duration of 10.1 years. In the majority of patients (68.3%) oral semaglutide was used as a second-line drug, mostly with metformin. At baseline, mean BMI was 28.9 kg/m

conclusionThis study supports oral semaglutide as an effective option for T2D treatment, offering improved glucose control and weight management in a real-world setting.

Indexed as

Blood GlucoseBody WeightDiabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsAdministration, OralAgedFemaleFollow-Up StudiesGlycated HemoglobinGlycemic ControlHumansMaleMiddle AgedRetrospective StudiesSemaglutideBlood GlucoseGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSemaglutideBody weightGlucose controlOral semaglutideReal-world effectivenessRetrospective studyType 2 diabetes

Identifiers

PMID38369592
PMCPMC11142994
OpenAlexW4391917570

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.